Leap Therapeutics, Inc. (LPTX) News

Leap Therapeutics, Inc. (LPTX): $1.17

-0.04 (-3.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LPTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter LPTX News Items

LPTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LPTX News Highlights

  • For LPTX, its 30 day story count is now at 4.
  • Over the past 15 days, the trend for LPTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • LEAP, ACT and VIR are the most mentioned tickers in articles about LPTX.

Latest LPTX News From Around the Web

Below are the latest news stories about Leap Therapeutics Inc that investors may wish to consider to help them evaluate LPTX as an investment opportunity.

10 Cheap Pharmaceutical Stocks For 2022

In this article, we discuss 10 cheap pharmaceutical stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Pharmaceutical Stocks For 2022. The pharma industry is in the midst of a fundamental transformation as disruptive technologies like artificial intelligence, machine learning, and natural language processing become […]

Yahoo | February 15, 2022

How Many Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Do Institutions Own?

Every investor in Leap Therapeutics, Inc. ( NASDAQ:LPTX ) should be aware of the most powerful shareholder groups...

Yahoo | February 8, 2022

Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...

Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.

Yahoo | February 3, 2022

Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (NASDAQ: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1 (DKK1). The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.

Yahoo | January 31, 2022

Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, and Cynthia Sirard, MD, Chief Medical Officer, will present a corporate overview at the B. Riley Securities Oncology Investor Conference. The conference will be held in a virtual meeting format.

Yahoo | January 24, 2022

Community Trust & Investment Co Buys Cheniere Energy Inc, Salesforce. ...

Lexington, KY, based Investment company Community Trust & Investment Co (Current Portfolio) buys Cheniere Energy Inc, Salesforce.com Inc, PayPal Holdings Inc, AstraZeneca PLC, The Walt Disney Co, sells Southwest Airlines Co, Lowe's Inc, Nike Inc, Norfolk Southern Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Community Trust & Investment Co.

Yahoo | January 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | January 19, 2022

Why Leap Therapeutics Stock Is Surging Today

Shares of Leap Therapeutics (NASDAQ: LPTX), a clinical-stage biopharmaceutical company, are surging in response to positive clinical results from a stomach cancer study. Last September, Leap Therapeutics stock more than doubled overnight after the company reported impressive response rate data for its lead candidate DKN-1 plus tislelizumab from BeiGene (NASDAQ: BGNE). The experimental combination treatment was tested among patients newly diagnosed with advanced-stage stomach cancer.

Yahoo | January 19, 2022

These 2 Nasdaq Stocks Are Poised to Make Big Moves Today

Tech and biotech stocks on the Nasdaq Stock Market have been taking a beating lately. Narrative-driven growth stocks have fallen out of favor since the start of last December due to the uncertainty created by sky-high inflation rates, the omicron variant, and the Federal Reserve's possible moves on the interest rate issue later this year. As a result, the impact of positive news on the share prices of pure-play growth stocks has been wildly unpredictable over the last few weeks.

Yahoo | January 19, 2022

Orphazyme Tightens FY21 Revenue Outlook

View more earnings on ORPHSee more from BenzingaUCB to Buy Epilepsy-Focused Zogenix In .9B Deal: See The HighlightsLeap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Yahoo | January 19, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.5949 seconds.